Bcl-2 and bax protein expression in indolent versus aggressive B-cell non-hodgkin's lymphomas
- 1 August 1998
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 29 (8) , 820-825
- https://doi.org/10.1016/s0046-8177(98)90451-8
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- REGULATION OF CLINICAL CHEMORESISTANCE BY bcl‐2 AND BAX ONCOPROTEINS IN B‐CELL CHRONIC LYMPHOCYTIC LEUKAEMIABritish Journal of Haematology, 1996
- Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.Journal of Clinical Oncology, 1996
- Bcl-2,Bax andp53 expression in B-CLL in relation toin vitro survival and clinical progressionInternational Journal of Cancer, 1996
- Bcl-2 family proteins: regulators of chemoresistance in cancerToxicology Letters, 1995
- Mechanisms of Apoptosis: Integration of Genetic, Biochemical, and Cellular IndicatorsJNCI Journal of the National Cancer Institute, 1994
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994
- BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with BaxNature, 1994
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapyBlood, 1993
- Bcl-2 initiates a new category of oncogenes: regulators of cell deathBlood, 1992